Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG priming before Comirnaty in health care workers
2021-000182-33Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of tozinameran and bcg vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Radboudumc. Primary endpoint: Seroconversion of IgG to SARS-CoV-2 spike protein at day 21 after first Comirnaty dose. Started Jan 2021; status: completed.
02
Drugs
tozinameranbcg vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000182-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000182-33.